- NEJM – Coronavirus
- ID_NEJM Infected Travelers_ SARS-COV-2
- Review Figure S1 -> This shows the SARS-COV-2 RNA amplification test is likely not 100% sensitive. There are likely a significant number of false negatives.
- Fecal samples positive for ~27 days after symptom onset.
- Fecal samples remain positive for ~11 days after respiratory samples are (-).
- No fecal – oral route cases have been reported.
- Randomize control study
- One center / small number of patients
- Stopped early as the helmet lead to reduced intubations
- Americal Society of Anesthesioloists -> Joint Statement on Multiple Patient Per Ventilator
- This is exceptionally dangerous
- ID_JAMA_Outcomes of 21 Critically Ill Patients in Washington State
- High rate of ARDS / death
- Myocardial Injury Common in Hospitalized COVID-19 Patients
- JAMA Ventalator Survival Rate is Poor
- JAMA – Management of COVID Respiratory Distress
- NEJM- Remdesivir for Treatment of COVID-19 (Final)
- Dexamethasone Reduces Death by up to 1/3 in Patients with Severe Respiratory Complications (Early Release)
- Lancet – RTC – Azithromycin + Standard of Care -> Did not improve outcomes
- Mild to Moderate COVID-19
- NEJM – Dexamethasone in Hospitalized Patients
- Lower 28-day mortality
- ACEP Now – Bounce Back Data
Diagnosis and Testing Guidelines